Related Experiment Videos
Clopidogrel as an antiplatelet agent in transplant heart coronary stenting
Vaikom S Mahadevan1, Mazhar M Khan, Jennifer A A Adgey
1Regional Medical Cardiology Centre, Royal Victoria Hospital, Grosvenor Rd., Belfast, BT12 6BA, United Kingdom. vsm@ntlworld.com
Insights
Clopidogrel and aspirin therapy enabled successful coronary stenting in a transplanted heart. This dual antiplatelet treatment preserved vessel patency, preventing in-stent restenosis at four months.
Area of Science:
- Cardiology
- Transplantation Medicine
- Pharmacology
Background:
- Coronary stenting is a common procedure for managing coronary artery disease.
- Dual antiplatelet therapy with aspirin and clopidogrel is standard post-stenting.
- Cardiac transplant recipients require careful management of cardiovascular complications.
Observation:
- This case report details direct coronary stenting in a patient with a transplanted heart.
- The procedure utilized clopidogrel and aspirin therapy.
Findings:
- Successful direct coronary stenting was achieved in the transplanted heart.
- Vessel patency was maintained post-procedure.
- Follow-up angiography at 4 months showed no evidence of in-stent restenosis.
Implications:
- Clopidogrel and aspirin therapy appears safe and effective for coronary stenting in cardiac transplant recipients.
- This approach may help prevent restenosis in this vulnerable patient population.
- Further studies are warranted to confirm these findings in larger cohorts.
Abstract:
Clopidogrel is increasingly used as an antiplatelet agent along with aspirin in coronary stenting due to its safety profile and clinical efficacy. This report describes a case of successful direct coronary stenting in a transplanted heart with the use of clopidogrel and aspirin therapy. Vessel patency was preserved with no evidence of in stent restenosis on 4-month follow-up angiography.